{"id":"W4387252273","doi":"10.1038/s41591-023-02589-w","title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network; University of Calgary; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"National Cancer Institute; SkylineDx; Genentech; MEI Pharma; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Gilead Sciences; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Clinical endpoint; Adverse effect; Cumulative incidence; Progression-free survival; Surgery; Oncology; Clinical trial; Chemotherapy; Cancer; Immunotherapy; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001222821,0.0008833791,0.001038592,0.0002378059,0.0002456174,0.0006677257,0.000542493,0.0007620404,0.002373126],"category_scores_gemma":[0.0005139729,0.0002190559,0.0008244365,0.0002107532,0.0003426913,0.0004937208,0.0002682546,0.00190155,0.000537122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007794352,"about_ca_system_score_gemma":0.0005776164,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004005694,"about_ca_topic_score_gemma":0.001100022,"domain_scores_codex":[0.9997608,0.0001242323,0.000009041033,0.00003467446,0.00002746058,0.00004378498],"domain_scores_gemma":[0.9998128,0.00003644724,0.00005745603,0.00001388209,0.00001178897,0.00006767457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5413426,0.01528035,0.007046668,0.002358079,0.002593814,0.0004036792,0.0002983159,0.005364942,0.03022489,0.001470073,0.01865137,0.3749652],"study_design_scores_gemma":[0.8381249,0.1221698,0.0162448,0.0002420349,0.001073176,0.000679743,0.0000491713,0.00406035,0.003884371,0.001004079,0.01242607,0.00004141942],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9715813,0.0206466,0.0005876161,0.001413565,0.000261303,0.0006999886,0.0007915787,0.0001448924,0.003873051],"genre_scores_gemma":[0.9806728,0.007822278,0.001401797,0.002494973,0.0003171122,0.001047516,0.00192136,0.00003169007,0.004290311],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002373126,"threshold_uncertainty_score":0.007938921,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04272326740296717,"score_gpt":0.3915068327786259,"score_spread":0.3487835653756587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}